SynRix is an early-stage venture focused on small-molecule synthesis, chemical intermediates, and process development. We are building capabilities to support pharmaceutical and biotech development — with an emphasis on speed, cost-efficiency, and practical execution.
SynRix is currently developing a focused set of capabilities in small-molecule chemistry — chosen for where we can move quickly and deliver real value to research and early development partners.
Made-to-order synthesis of small molecules to support discovery, screening, and early development chemistry — with scope, timeline, and deliverables defined up front.
Sourcing and building chemical intermediates and precursor compounds where existing supply is constrained, costly, or unreliable for downstream development work.
Evaluating alternative synthetic routes to reduce step count, improve yield, and surface paths that are cheaper or more practical to execute at the next scale.
Translating bench-scale chemistry into reproducible, documented procedures — preparing the groundwork needed for partners to scale through external manufacturing relationships.
We focus on practical, execution-oriented chemistry that supports research and early development workflows.— SynRix operating principle
Operating as an early-stage venture, with the focus and flexibility that comes with it.
Standing up the technical infrastructure required to execute synthesis and process work in-house.
Planning collaboration within Chicago's research environment, including Hyde Park Labs and the University of Chicago.
Actively seeking pilot projects, research collaborations, and grant opportunities that align with our focus areas.
SynRix is most useful to teams who need execution-focused chemistry support and who value clarity about scope, timing, and deliverables.
Companies that need bench-scale synthesis or intermediate support without standing up dedicated chemistry teams.
University labs and PIs working on small-molecule chemistry where collaboration on synthesis or scale support would help move work forward.
Organizations developing new chemical compounds and looking for execution-focused partners on synthesis, intermediates, or process work.
Organizations working to improve resilience and reliability in pharmaceutical supply chains for critical compounds.
Our scope is intentionally narrow. These are the four areas where we believe early-stage execution can produce the most useful results — and where we're prioritizing capability-building.
Building blocks that sit upstream of API and active compound synthesis, where supply gaps and pricing volatility are common.
Functional molecular fragments used across discovery, screening, and early development chemistry workflows.
Routes engineered for fewer steps, lower-cost reagents, and reduced purification burden — improving the economics of downstream work.
Critical compounds where reliable, alternative sourcing or domestic execution would meaningfully reduce risk for partners.
We're keeping the early playbook clear — identify the right work, evaluate the chemistry, validate it through partnership, and prepare it for scale through outside relationships when the time comes.
Surface target molecules and collaboration opportunities aligned with our focus areas — biased toward problems where execution-focused chemistry produces a clear, near-term result.
Develop or evaluate synthesis approaches with an emphasis on practicality, cost discipline, and route options that hold up under real-world constraints.
Validate through structured lab work and research partnerships — small enough to move quickly, rigorous enough to inform what scales.
Prepare the validated chemistry for future scale through external manufacturing relationships, rather than building heavy infrastructure in-house ahead of demand.
SynRix was founded to address inefficiencies in the pharmaceutical supply chain by focusing on practical chemical development and execution — the work that actually has to happen between an idea and a manufacturable compound.
The company is led by an operator with over fifteen years of experience building and managing healthcare primary care clinics, with a focus on scaling operations, improving efficiency, and delivering real-world results. That operator's lens — bias toward execution, clarity about cost, comfort with iteration — shapes how SynRix approaches chemistry partnerships.
SynRix is actively building relationships across the early ecosystem we'll need to do useful work — locally and beyond.
University research groups working on small-molecule chemistry, intermediates, and adjacent areas where collaboration can advance shared interests.
Programs and institutes working on pharmaceutical innovation, supply-chain resilience, and translational chemistry.
Contract research organizations and external manufacturing partners who can extend SynRix's capabilities as work scales.
We're early, we're focused, and we're actively looking for the right first projects. Send us a target structure, a research question, a collaboration proposal, or a grant opportunity.
info@Syn-Rix.com